ArticleThe Journal of experimental medicine2020
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.
Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate.The Korean journal of internal medicine · 2023Trial
- MGANSL: multi-network representation generating with generative adversarial network for synthetic lethality prediction.BMC bioinformatics · 2025Article
- RAS Pathway Mutations and Therapeutics in Vascular Anomalies.Pediatric blood & cancer · 2025Review
- Lyve1-Driven NrasPediatric blood & cancer · 2025Article
- Lymphatic System Development and Function.Current cardiology reports · 2024Review
- Pathologic features of brain hemorrhage after radiation treatment: case series with somatic mutation analysis.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2024Article
- Congenital Vascular and Lymphatic Diseases.Circulation research · 2024Review
- ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection.Nature communications · 2024Article
- HighMedicina (Kaunas, Lithuania) · 2023Article
- P-21 Activated Kinases in Liver Disorders.Cancers · 2023Review
- Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib.JCI insight · 2022Article
- Digital Staging of Hepatic Hemangiomas Reveals Spatial Heterogeneity in Endothelial Cell Composition and Vascular Senescence.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- KRAS protein expression becomes progressively restricted during embryogenesis and in adulthood.Frontiers in cell and developmental biology · 2022Article
- Vascular and Lymphatic Malformations: Perspectives From Human and Vertebrate Studies.Circulation research · 2021Article
- Cutaneous and hepatic vascular lesions due to a recurrent somaticHGG advances · 2021Article
- An Update on the Roles of circRNA-ZFR in Human Malignant Tumors.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Human hepatic vascular cavernomas, the most common benign tumor of the liver, were described in the mid-1800s, yet the mechanisms for their formation and effective treatments remain unknown. Here, we demonstrate gain-of-function mutations in KRAS or BRAF genes within liver endothelial cells as a causal mechanism for hepatic vascular cavernomas. We identified gain-of-function mutations in KRAS or BRAF genes in pathological liver tissue samples from patients with hepatic vascular cavernomas. Mice expressing these human KRASG12D or BRAFV600E mutations in hepatic endothelial cells recapitulated the human hepatic vascular cavernoma phenotype of dilated sinusoidal capillaries with defective branching patterns. KRASG12D or BRAFV600E induced "zipper-like" contiguous expression of junctional proteins at sinusoidal endothelial cell-cell contacts, switching capillaries from branching to cavernous expansion. Pharmacological or genetic inhibition of the endothelial RAS-MAPK1 signaling pathway rescued hepatic vascular cavernoma formation in endothelial KRASG12D- or BRAFV600E-expressing mice. These results uncover a major cause of hepatic vascular cavernomas and provide a road map for their personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.